Hemostasis and glycemic control in the cardiac surgical patient

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 10, Issue 2, 2006, Pages 176-179

  Slaughter, Thomas F ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular risk; Diabetes mellitus; Hemostasis; Perioperative glucose control

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

AGE; ANGINA PECTORIS; ATHEROSCLEROSIS; BLINDNESS; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEART SURGERY; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERINSULINEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LIMB AMPUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULAR ENDOTHELIUM;

BLOOD GLUCOSE; CARDIAC SURGICAL PROCEDURES; CEREBROVASCULAR ACCIDENT; CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; DIABETES COMPLICATIONS; HEMOSTASIS; HUMANS; INSULIN; RISK FACTORS;

EID: 33747467219     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253206288993     Document Type: Conference Paper

References (18)

1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333-1346.
2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581.
3. Winer N, Sowers JR. Epidemiology of diabetes. J Clin Pharmacol. 2004;44:397-405.
4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428.
5. Barr RG, Nathan DM, Meigs JB, et al. Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med. 2002;137:263-272.
6. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
7. Luscher TF, Creager MA, Beckman JA, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation. 2003; 108: 1655-1661.
8. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-240.
9. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol. 2004; 44: 2293-2300.
10. Pandolfi A, Giaccari A, Cilli C, et al. Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetol. 2001;38:71-76.
11. Rao AK, Chouhan V, Chen X, et al. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes. 1999;48:1156-1161.
12. Hughes A, McVerry BA, Wilkinson L, et al. Diabetes, a hypercoagulable state? Haemostatic variables in newly diagnosed type 2 diabetic patients. Acta Haemat. 1983;69: 254-259.
13. Sjoholm A, Nystrom T. Endothelial inflammation in insulin resistance. Lancet. 2005;365:610-612.
14. Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly. 2002;132: 241-252.
15. Creager MA, Luscher TF, Consentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003; 108:1527-1532.
16. Ferroni P, Basili S, Falco A, et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2:1282-1291.
17. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care. 2002;25(suppl 1):S78-S79.
18. Davi G, Gresele P, Violi F, et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo: evidence derived from the study of peripheral arterial disease. Circulation. 1997;96:69-75.